Key Takeaways

KPV is commonly described as an anti-inflammatory, gut-support, or wound-healing peptide, but the most important scientific distinction is that it is a short synthetic tripeptide derived from the C-terminal sequence of α-MSH, not the same thing as full-length α-MSH or a specialized KPV nanoparticle, hydrogel, conjugate, or analogue.
The strongest evidence is preclinical, especially human intestinal-cell experiments and mouse colitis models, where KPV has been studied for PepT1-mediated uptake and reduced inflammatory signaling through pathways such as NF-κB and MAPK.
Additional studies have explored narrower preclinical roles in rabbit corneal wound healing, keratinocyte and bronchial epithelial-cell models, antimicrobial assays, and mouse brain-injury models.
These studies support scientific plausibility in limited experimental contexts, but they do not establish that compounded KPV free base or KPV acetate treats inflammatory bowel disease, heals wounds, improves skin disease, fights infection, or reduces systemic inflammation in humans.
KPV is therefore best described as investigational, unapproved, and supported mainly by cell, animal, and formulation-specific evidence, not as a clinically proven anti-inflammatory, gut-healing, wound-healing, or immune-balancing treatment.

‍

[FDA, 2026; PubChem, 2026; Dalmasso et al., 2008; Kannengiesser et al., 2008; Bonfiglio et al., 2006; Land, 2012].

‍

KPV: An investigational synthetic tripeptide modeled on the C-terminal Lys-Pro-Val segment of α-melanocyte-stimulating hormone, corresponding to residues 11–13 of α-MSH — canonical sequence KPV.

Overview

KPV is commonly described as the Lys-Pro-Val tail of α-melanocyte-stimulating hormone. The general public frequently blurs the lines between the parent hormone, unmodified tripeptide, salt form, terminally modified variants, analogues, and carrier-dependent formulations when those lines shouldn't be blurred. According to the FDA, KPV (free base) and KPV acetate are separate compounds and distinct from MSH (11-13) and L-lysyl-L-prolyl-L-valine acetate. On July 23, 2026, the Pharmacy Compounding Advisory Committee voted 8-6, with one abstention, to recommend adding both forms to the 503A Bulks List; the recommendation is non-binding, and FDA has not taken final action. [FDA, 2026; PubChem, 2026; Reuters, 2026]

What it is

KPV is shorthand for the amino-acid sequence lysine–proline–valine, commonly written Lys-Pro-Val or KPV. It corresponds to the final three residues of α-MSH and is also commonly described as α-MSH(11-13) or MSH (11-13). PubChem currently maintains separate compound records for MSH (11-13) and L-lysyl-L-prolyl-L-valine acetate, while FDA records currently distinguish KPV (free base) from KPV acetate.

Material	What it is	Why it cannot be collapsed into "KPV"
Full-length α-MSH	Parent tridecapeptide containing the KPV tail	Includes additional residues and broader melanocortin biology, including pigment-related pharmacology.
KPV acetate	Acetate salt entry and FDA-reviewed salt-form designation	Salt form is not the same thing as covalent N-terminal acetylation, and should not be written as if it were "acetylated KPV."
KPV-NH₂	C-terminally amidated KPV	Terminal chemistry differs and may alter behavior, handling, or cited evidence.
Ac-KPV-NH₂	N-acetylated, C-amidated variant	Distinct intervention with different termini than plain KPV.
KdPT and other analogues	Related tripeptide analogues	Analogue data are not same-molecule KPV data.
KPV nanoparticles, hydrogels, prodrugs, conjugates	Delivery-system interventions, not KPV itself	Efficacy may depend on carrier, targeting chemistry, release profile, and route as much as on the KPV motif itself.

How it's proposed to work

The most defensible mechanistic anchor is the intestinal inflammation literature. Dalmasso et al. is the key KPV uptake and intestinal-inflammatory-signaling paper, and the broader Endocrine Reviews article by Brzoska et al. support the larger framing that KPV is the non-pigmentary C-terminal α-MSH tripeptide advanced as an anti-inflammatory alternative to full-length α-MSH. In that broader review, α-MSH and related tripeptides are linked to inflammatory pathways including NF-κB, cytokine production, inflammatory-cell migration, and apoptosis, with KPV highlighted because it preserves anti-inflammatory activity without pigmentary effect. [Brzoska, 2008]

KPV is best described as a preclinical anti-inflammatory signaling candidate, not a clinically established anti-inflammatory therapy. That conclusion is supported by FDA's human-exposure warning, the FDA's 2026 briefing findings, and the broader review literature. [FDA, 2026; Brzoska, 2008]

Common forms in circulation

FDA's 2026 review treated KPV (free base) and KPV acetate as separate bulk drug substances and evaluated 0.1% cream and gel for topical administration for wound healing and inflammatory conditions. The briefing document noted that KPV showed low permeability through human cadaver skin, which could limit topical effectiveness; the July 23 vote did not validate that route or those uses. [FDA, 2026; Reuters, 2026]

Current market pages present KPV through a range of formats and protocols, including injectable, oral, topical, and occasionally stacked or blended formats. Some describe KPV as investigationally used for gut integrity, skin health, and systemic inflammation support, stating that depending on protocol it may be administered orally, topically, or via injection. Those pages are useful as market-behavior evidence, not as proof of validated KPV route equivalence or human efficacy. [Huemn, 2026; Robertson Wellness & Aesthetics, 2026]

Names and aliases

Scientific and market aliases that circulate around KPV include KPV, Lys-Pro-Val, L-lysyl-L-prolyl-L-valine, α-MSH(11-13), MSH 11-13, KPV (free base), and KPV acetate. The most important is KLOW, which current clinic and journalism sources describe as a blend that includes KPV, GHK-Cu, TB-500, and BPC-157. The New Yorker described a user ordering exactly that blend. [The New Yorker, 2026; Agullo, 2026; Preferred Regen ATL, 2025]

Regulatory status

KPV has no identified FDA-approved human indication. FDA's current safety-risk page explains that substances with potential significant safety risks were placed in Category 2 under the interim policies, and it separately lists bulk drug substances nominated but withdrawn — defined there as substances previously in category 2 of the interim policies that were withdrawn by the nominators. KPV appears in that withdrawn list, and FDA states that it has not identified any human exposure data for KPV-containing drug products by any route and lacks important information regarding whether KPV would cause harm if administered to humans. [FDA, 2026]

On July 23, 2026, the Pharmacy Compounding Advisory Committee met to reconsider KPV free base and acetate for potential inclusion on the 503A Bulks List, evaluating a nominated 0.1% topical cream and gel for wound healing and inflammatory conditions. FDA staff had recommended against inclusion, concluding that both substances were not well characterized, the extent of historical compounding use was unknown, no clinical studies or human exposure data had been identified, and available information was insufficient to determine clinical safety or effectiveness. The committee nonetheless voted 8-6, with one abstention, to recommend adding both KPV (free base) and KPV acetate to the 503A Bulks List. [FDA, 2026; Reuters, 2026]

The recommendation is advisory only: FDA has not added either substance to the 503A Bulks List, and the vote does not itself authorize compounding, establish clinical effectiveness, or validate any specific route, protocol, or disease claim. [FDA, 2026]

Evidence base

Evidence tier	What qualifies	What it does not justify
Clinical trial	Same-molecule, human interventional research using the same form, route, and intended outcome.	Turning cell or animal data into human efficacy claims.
Animal model	In vivo work using a clearly described KPV-related intervention.	Human efficacy, human dosing, route equivalence, or long-term safety.
Mechanistic hypothesis	Cell, tissue, transporter, pathway, receptor, or in-vitro antimicrobial work.	Claims about disease treatment, symptom control, healing, or patient outcomes.
Anecdotal or commercial	Clinic pages, influencer claims, market stacks, testimonials, or research-chemical marketing.	Any efficacy or safety conclusion.

Purported benefits, by evidence strength

Purported benefit	Tagged evidence strength	What the evidence supports	What it does not support
KPV reduces inflammation in humans	No identified clinical tier; mechanistic and animal evidence	Preclinical studies support inflammatory signaling effects and animal-model anti-inflammatory findings. FDA found insufficient evidence to evaluate effectiveness for the nominated inflammatory uses.	"Clinically proven anti-inflammatory," established human dose, or established human safety.
Ulcerative colitis, Crohn disease, or inflammatory bowel disease	Animal model plus cell mechanism	Experimental intestinal inflammation, including murine colitis and transporter/signaling work.	Human IBD treatment, remission claims, or replacement of approved therapy.
Gut-barrier repair, mucosal healing, or "leaky gut"	Animal model, often delivery-system-specific	Certain animal-model and carrier-based studies report improved mucosal or inflammatory outcomes.	"Heals leaky gut," repairs human intestinal lining, or proves plain oral KPV efficacy.
Wound healing	Rabbit animal model and formulation-specific model evidence; no identified human clinical tier for the nominated topical use.	Older corneal-wound work and some formulation-specific preclinical healing readouts. FDA's review also noted low KPV permeability through human cadaver skin, which could limit topical effectiveness.	Generic skin-wound healing, scar reduction, post-surgical recovery, tendon healing, validated topical efficacy, or other human benefit.
Dermatology and skin calming	Cell and experimental skin-model evidence	Keratinocyte and skin-model signaling work, including newer oxidative stress/MAPK/NF-κB work.	Treatment of eczema, psoriasis, rosacea, acne, dermatitis, or cosmetic outcomes in patients.
Airway inflammation	Mechanistic cell evidence	Inflammatory-signaling effects in bronchial epithelial cells.	Asthma, COPD, or respiratory-disease treatment.
Antibacterial or antifungal activity	In-vitro evidence	Laboratory antimicrobial activity under experimental conditions.	Infection treatment in humans.
Neuroprotection or pain reduction	Animal model only	Mouse brain-injury and older inflammatory/pain-related animal signals.	Treatment of concussion, TBI, chronic pain, headache, or mood symptoms in humans.

Key literature

Dalmasso G, Charrier-Hisamuddin L, Nguyen HT, Yan Y, Sitaraman S, Merlin D. PepT1-mediated tripeptide KPV uptake reduces intestinal inflammation. Gastroenterology. 2008;134(1):166-178. Core PepT1, NF-κB, MAPK, cytokine, and murine-colitis findings.

Kannengiesser K, Maaser C, Heidemann J, et al. Melanocortin-derived tripeptide KPV has anti-inflammatory potential in murine models of inflammatory bowel disease. Inflamm Bowel Dis. 2008;14(3):324-331. Reproducible preclinical GI signal in two mouse colitis models.

Brzoska T, Luger TA, Maaser C, Abels C, Böhm M. α-Melanocyte-Stimulating Hormone and Related Tripeptides: Biochemistry, Antiinflammatory and Protective Effects in Vitro and in Vivo, and Future Perspectives for the Treatment of Immune-Mediated Inflammatory Diseases. Endocr Rev. 2008;29(5):581-602. High-level synthesis of α-MSH, KPV, pigmentary distinctions, pathways, and model data.

Bonfiglio V, Camillieri G, Avitabile T, Leggio GM, Drago F. Effects of the COOH-terminal tripeptide alpha-MSH(11-13) on corneal epithelial wound healing: role of nitric oxide. Exp Eye Res. 2006;83(6):1366-1372. Rabbit corneal wound-healing signal and nitric oxide link.

Xiao B, Xu Z, Viennois E, et al. Orally Targeted Delivery of Tripeptide KPV via Hyaluronic Acid-Functionalized Nanoparticles Efficiently Alleviates Ulcerative Colitis. Mol Ther. 2017;25(7):1628-1640. Carrier-dependent colon-targeted KPV delivery in colitis models.

References

U.S. Food and Drug Administration. July 23-24, 2026: Meeting of the Pharmacy Compounding Advisory Committee.
U.S. Food and Drug Administration. July 23-24, 2026 Meeting of the Pharmacy Compounding Advisory Committee — FDA Briefing Document for KPV-Related Bulk Drug Substances. May 12, 2026.
U.S. Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding that May Present Significant Safety Risks. Content current April 22, 2026.
U.S. Food and Drug Administration. Bulk Drug Substances Nominated for Use in Compounding Under Section 503A of the Federal Food, Drug, and Cosmetic Act. Updated May 14, 2026.
PubChem. MSH (11-13).
PubChem. L-lysyl-L-prolyl-L-valine acetate.
Reuters. US FDA to convene expert panel to review wider access to some peptides. April 15, 2026.
Reuters. FDA advisers back first four of seven unapproved peptides under review for looser rules. July 23, 2026.
Allure. The FDA May Reverse a Ban on Several Peptides With Potential Beauty Benefits. What Does That Mean, Exactly? 2026.
The New Yorker. Why Are People Injecting Themselves with Peptides? April 6, 2026.

‍

KPV